|Titre :||Global Drug Survey (GDS) 2021. Key findings report|
|Auteurs :||A. R. WINSTOCK ; L. J. MAIER ; A. ZHUPARRIS ; E. DAVIES ; C. PULJEVIC ; K. P. C. KUYPERS ; J. A. FERRIS ; M. J. BARRATT|
|Type de document :||Rapport|
|Année de publication :||2021|
|Format :||27 p.|
|Discipline :||EPI (Epidémiologie / Epidemiology)|
Thésaurus TOXIBASEENQUETE ; PRODUIT ILLICITE ; ALCOOL ; TABAC ; CANNABIS ; CIGARETTE ELECTRONIQUE ; OPIOIDES ; HALLUCINOGENES ; EVOLUTION ; DROGUES DE SYNTHESE ; EPIDEMIE ; PLAISIR
Data collection period: GDS2021 ran between December 2020 and March 2021.
Sample characteristics Global Drug Survey 2021 (GDS2021):
Data from over 32,000 people from over 20 countries were used in the preparation of this report. 62% were cisgender men, 34% were cisgender women, and 3.5% were either transgender, non-binary, or intersex. 30% were aged under 25 years (the sample was older than GDS2020, where 52% were aged 25 years and younger) with 38.5% aged 35 years or older (compared to 22% in GDS2020). 86% of the sample identified as white. 47% had at least an undergraduate degree as their highest level of educational attainment. 40% reported a lifetime diagnosis of any mental health or neurodevelopmental condition.
Compared to GDS2020, there were falls in the rates of almost all drug classes. This might reflect the older age of the GDS2021 sample or reflect the trend we have seen in most drugs (most notably stimulants) being used less frequently during the COVID-19 pandemic. The data also confirm the widespread use of CBD products globally with CBD being used by more people in the last 12 months than any other drug except alcohol, tobacco and THC containing cannabis.
|Domaine :||Alcool / Alcohol ; Autres substances / Other substances ; Drogues illicites / Illicit drugs ; Tabac / Tobacco|
|URL :||Executive summary|